文献速递免疫规划

新型MAV/06株水痘疫苗在健康儿童中的免疫原性与安全性:多国多中心随机双盲III期研究

Immunogenicity and safety profiles of a new MAV/06 strain varicella vaccine in healthy children: A multinational, multicenter, randomized, double-blinded, active-controlled phase III study.
PubMed 文献 · Vaccine · 2021-02-21

该III期随机双盲多中心研究在韩国和泰国纳入515名12月龄至12岁健康儿童,按1:1比较新型MAV/06株水痘疫苗MG1111与对照疫苗Varivax的免疫原性和安全性。结果显示MG1111组血清阳转率97.9%(95%CI:95.2-99.3),血清阳转率差异95%CI下限为-4.0%高于非劣效界值-10%,GMT从2.0升至74.2(95%CI:65.0-84.8),GMT比值95%CI下限0.55高于预设参数0.5。两组不良事件和严重不良事件发生率无显著差异。

要点

  • MG1111组血清阳转率97.9%,非劣效于Varivax。
  • MG1111组GMT从2.0升至74.2,GMT比值非劣效于对照。
  • 两组不良事件和严重不良事件发生率无显著差异。

核心结论

  • MG1111在免疫原性上非劣效于Varivax,安全性特征与Varivax相似。

研究设计与样本

  • III期随机双盲多中心活性对照研究,在韩国和泰国开展,纳入515名12月龄至12岁健康儿童,按1:1随机分配至MG1111组(258人)或对照疫苗Varivax组(257人)。

主要发现

  • MG1111组接种后血清阳转率为97.9%(95%CI:95.2-99.3)。
  • 血清阳转率差异(MG1111-Varivax)的95%CI下限为-4.0%,高于预设非劣效界值-10%。
  • MG1111组GMT从2.0升至74.2(95%CI:65.0-84.8)。
  • 接种后GMT比值(MG1111/Varivax)的95%CI下限为0.55,高于预设参数0.5。
  • 在43天观察期内,两组在征集性、局部或全身不良事件百分比上无显著差异;在6个月观察期内,严重不良事件也无显著差异。

关键数值与推荐

  • 血清阳转率非劣效界值:-10%。
  • GMT比值非劣效参数:0.5。

临床怎么用

  • MG1111可作为水痘预防的候选疫苗,其免疫原性非劣效于Varivax且安全性相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunization is the most effective preventive strategy against varicella. While the Oka strain is commonly used for varicella vaccination worldwide, Korea widely uses the MAV/06 strain. A new live attenuated MAV/06 strain varicella vaccine (MG1111), which uses the new cell line Medical Research Council-5 for better viral propagation, was developed. MG1111 was approved by Korean health authorities. Here, we report the results of phase III, randomized, double-blind, multicenter study conducted in Korea and Thailand, which compared the immunogenicity and safety profiles of MG1111 versus the control vaccine, VarivaxTM. In total, 515 healthy children (12 month-12 years) were randomized 1:1 to receive either the MG1111 or control vaccine (MG1111: 258, Control: 257). The seroconversion rate (SCR) and geometric mean titer (GMT) were measured using the fluorescent antibody to membrane antigen (FAMA) test. The MG1111 group achieved a SCR of 97.9% (95% CI: 95.2-99.3) after vaccination. The lower limit of 95% CI for SCR difference (MG1111-VarivaxTM) was -4.0%, which was higher than the specified non-inferiority margin of -10%. Further, the GMT of the MG1111 increased from 2.0 to 74.2 (95% CI: 65.0-84.8) and the lower limits of the 95% CI for post-vaccination GMT ratios (MG1111/VarivaxTM) were 0.55 higher than the specified parameter of 0.5. Therefore, the MG1111 group was not statistically inferior to the control vaccine group in terms of SCR and GMT. Furthermore, the MG1111 and control vaccine groups were not significantly different in the percentage of participants showing adverse events-solicited, local, or systemic during 43-day period of observation and serious adverse events during 6 month of observation. The present results indicate that MG1111was not immunologically inferior to VarivaxTM, and safety profiles of MG1111 are similar to those of VarivaxTM.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Choi UY, Kim KH, Lee J, et al. Immunogenicity and safety profiles of a new MAV/06 strain varicella vaccine in healthy children: A multinational, multicenter, randomized, double-blinded, active-controlled phase III study. Vaccine. 2021. PMID: 33627245. doi:10.1016/j.vaccine.2021.02.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。